Literature DB >> 10698015

Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats.

R H Wang1, C Bejar, M Weinstock.   

Abstract

This study compared the effect of rivastigmine on cholinesterase (ChE) activity in different brain regions, heart, skeletal muscle and plasma and on the cognitive impairment induced by scopolamine (0.5 mg/kg) in male and female rats. Rats were injected s.c. with saline or rivastigmine (0.75-2.5 mg/kg) or physostigmine (0.05 mg/kg) and killed 30-120 min later. Amelioration of scopolamine-induced memory deficits by rivastigmine (0.75 mg/kg) was assessed in the Morris water maze. There were no gender differences in spatial memory or basal ChE activity in the brain or other organs. Rivastigmine (0.75 and 1.5 mg/kg) and physostigmine (0.05 mg/kg) caused significantly greater ChE inhibition in females than in males (P<0.01) in the cerebral cortex, hippocampus and striatum, but not in the periphery 30 and 60 min after injection. Rivastigmine was also more effective in antagonising the scopolamine-induced spatial memory impairment in female than in male rats. Ovariectomy did not affect the degree of enzyme inhibition by rivastigmine in any brain area. Orchidectomy completely abolished the difference in enzyme inhibition. It is concluded that a testicular hormone suppresses the effect of rivastigmine, by reducing the amount of drug reaching the brain or its interaction with ChE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698015     DOI: 10.1016/s0028-3908(99)00157-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  15 in total

1.  Asymmetry of fetal cerebral hemispheres: in utero ultrasound study.

Authors:  R Hering-Hanit; R Achiron; S Lipitz; A Achiron
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-11       Impact factor: 5.747

2.  Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.

Authors:  Michelle M Mielke; Jeannie-Marie Leoutsakos; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; JoAnn T Tschanz; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

3.  Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

Authors:  Anushka V Goonawardena; Lianne Robinson; Robert E Hampson; Gernot Riedel
Journal:  Learn Mem       Date:  2010-09-28       Impact factor: 2.460

Review 4.  Sex as a biological variable in the pathology and pharmacology of neurodegenerative and neurovascular diseases.

Authors:  Pedram Honarpisheh; Louise D McCullough
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

Review 5.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

6.  Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats.

Authors:  Marta Weinstock; Corina Bejar; Donna Schorer-Apelbaum; Rony Panarsky; Lisandro Luques; Shai Shoham
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-17       Impact factor: 4.147

7.  Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.

Authors:  Pedro J Modrego; Consuelo Rios; José M Pérez Trullen; Maria J García-Gómara; José M Errea
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction.

Authors:  Lianne Robinson; Anushka V Goonawardena; Roger Pertwee; Robert E Hampson; Bettina Platt; Gernot Riedel
Journal:  Behav Brain Res       Date:  2010-01-14       Impact factor: 3.332

9.  [11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors.

Authors:  Hans Jc Buiter; Albert D Windhorst; Marc C Huisman; Maqsood Yaqub; Dirk L Knol; Abraham Fisher; Adriaan A Lammertsma; Josée E Leysen
Journal:  EJNMMI Res       Date:  2013-03-21       Impact factor: 3.138

10.  Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause.

Authors:  Virginia M Miller; Vesna D Garovic; Kejal Kantarci; Jill N Barnes; Muthuvel Jayachandran; Michelle M Mielke; Michael J Joyner; Lynne T Shuster; Walter A Rocca
Journal:  Biol Sex Differ       Date:  2013-03-28       Impact factor: 5.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.